Obesity is a significant health concern that can lead to chronic disease such as diabetes, heart disease and stroke. While lifestyle changes such as exercise and diet are essential for weight management, medical treatments can also play a significant role in assisting individuals achieve their weight loss goals and improve their overall health.
At Anew You Med Spa we offer several options for our clients that are based on individual evaluations and then tailored to that individual.
Tirzepatide is one such medication. Tirzepatide is the active ingredient in Zepbound and Monjauro and is composed of a linear peptide molecule containing 39 amino acids. . Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by regulating insulin and glucagon, leading to reduced appetite, delayed gastric emptying, and improved glucose control, all contributing to weight loss.
Tirzepatide is different from Semaglutide in that the key differences is Tirzepatide is a “dual agonist” and Semaglutide targets only one receptor and that is the GLP-1.
What does this mean for you?
This means dual targeting may result in a greater weight loss and better glucose control. However, Tirzepatide is a newer treatment and may cost more.
Dosages
Dosages of tirzepatide for weight loss vary and are determined based on individual factors. Laura, your Nurse Practitioner at Anew You will prescribe an appropriate dosage, often titrate up gradually to achieve optimal results while minimizing potential side effects.
Who Should Not Take Tirzepatide?
- Hypersensitivity: If an individual is hypersensitive or allergic to tirzepatide or any of its ingredients such as paracetol, they should not take this medication.
- Medullary Thyroid Carcinoma (MTC): Tirzepatide may increase the risk of MTC, a type of thyroid cancer. Therefore, it is not recommended for individuals with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Diabetic Ketoacidosis (DKA): Tirzepatide is not recommended for the treatment of diabetic ketoacidosis, a serious complication of diabetes that requires emergency medical treatment.
- Pancreatitis: Tirzepatide may increase the risk of pancreatitis, a potentially life threatening condition. Individuals with a history of pancreatitis or who have elevated levels of pancreatic enzymes should not take this medication.
- Severe Gastrointestinal Disease: Tirzepatide may worsen gastrointestinal disease, including inflammatory bowel disease, gastroparesis, and other severe gastrointestinal conditions.
Side Effects
Nausea, elevated heart rate, constipation, reduced appetite, gallbladder disease, low blood sugar, diarrhea, stomach pains,
The risk are low (but not zero) and most occur at higher doses. We can offer zofran for nausea.
Your individual weight loss depends on many biologic factors including the duration and dosages that you receive. While individual results may vary, customers may potentially achieve weight loss targets of up to 30 pounds in the first three months of treatment, and possibly 50 pounds after 6 months.
Tirzepatide comes in the form of a sterile liquid solution that is administered via subcutaneous injection once a week in a medically supervised atmosphere.